Phase Ib/II Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma.
Phase of Trial: Phase I/II
Latest Information Update: 30 Aug 2017
At a glance
- Drugs ALT 801 (Primary) ; Cisplatin
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Altor BioScience Corporation
- 23 Jan 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 12 Mar 2013 Planned End Date changed from 1 Sep 2012 to 1 Sep 2013, as reported by ClinicalTrials.gov.
- 12 Mar 2013 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.